MedFactory receives US FDA approval to add medium-dose patient group to Phase 2 trial of Vatiquinone (Baptiserp)
Predicted impact: Low
Mid-dose cohort FDA approval for Phase 2 trial already reported in recent days.
MedPacto메드팩토
235980 · KOSDAQ · ₩235980 · 메드팩토
₩2,970▲ ₩45 (1.54%)End-of-day · Oct 29, 2026 · End-of-day prices.
Price · 1Y −34.36%
- Market cap
- ₩102B
- Enterprise value
- ₩68B
- P/E
- —
- P/B
- 2.6×
- Dividend yield
- 0.0%
- ROE
- −35.8%
- Net margin
- −283.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−65.7% from the high
₩2,235Today: ₩2,865 – ₩3,060₩8,650
Returns
- 1W−7.8%
- 1M+2.1%
- 3M+32.6%
- 6M−42.0%
- YTD−55.5%
- 1Y−34.4%
- Volume today
- 92,922
- 0.9× the 20-day average
- Traded today
- ₩274M
- Listed shares
- 34,275,121
- EPS (12 months)
- −₩413
- Earnings yield −13.9%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 40 of 100 (50 is a normal day for this stock).
- MomentumFlat3.8% over the last month; the price is below its 20-day average.
- News impactSome3 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
MedPacto stock overview
MedPacto (메드팩토, KRX: 235980) is listed on KOSDAQ, in the Biotech & Pharma sector. MedFactory is a South Korean drug developer spun off in 2013 from Theragen Etex's new drug research institute, focused on innovative cancer and chronic disease therapies discovered with advanced genome analysis. Its shares closed at ₩2,970 on Oct 29, 2026, up 1.54% on the day, giving it a market value of ₩102B.
Key facts
- Market cap
- ₩102B
- Sector
- Biotech & Pharma
- Latest price change
- +1.54%
- As of
- Oct 29, 2026
- Main business
- MedFactory is a South Korean drug developer spun off in 2013 from Theragen Etex's new drug research institute, focused on innovative cancer and chronic disease therapies discovered with advanced genome analysis.
Quick answers about MedPacto
- What does MedPacto do?
- MedFactory is a South Korean drug developer spun off in 2013 from Theragen Etex's new drug research institute, focused on innovative cancer and chronic disease therapies discovered with advanced genome analysis. Its lead pipeline, vactosertib, is a small-molecule TGF-β1 signaling inhibitor being studied alone and combined with immunotherapies and chemotherapies for intractable solid tumors in the United States and Korea. The company also develops MP010, a fusion protein targeting the tumor microenvironment, and MP2021 for bone and autoimmune diseases.
- What is the market cap of MedPacto?
- The market capitalisation of MedPacto was ₩102B at the close on Oct 29, 2026.
- Who are the largest shareholders of MedPacto?
- According to the latest official filings, the largest reported holders are Teragen Etex (19.61%, as of Mar 21, 2025); Kim Seong-jin (7.76%, as of Mar 21, 2025); National Pension Service (2.96%, as of Dec 31, 2023).
- When is the next earnings report from MedPacto?
- Korean companies rarely announce results dates in advance. Based on when MedPacto filed the same report in past years, its next 3q results is expected between Nov 3, 2026 and Nov 14, 2026.
- Does the National Pension Service own MedPacto?
- Yes. The National Pension Service held 2.96% of MedPacto shares as of Dec 31, 2023.
Company profile
MedFactory is a South Korean drug developer spun off in 2013 from Theragen Etex's new drug research institute, focused on innovative cancer and chronic disease therapies discovered with advanced genome analysis. Its lead pipeline, vactosertib, is a small-molecule TGF-β1 signaling inhibitor being studied alone and combined with immunotherapies and chemotherapies for intractable solid tumors in the United States and Korea. The company also develops MP010, a fusion protein targeting the tumor microenvironment, and MP2021 for bone and autoimmune diseases.
Written by AI from the company's latest annual report.
- Korean name
- 메드팩토
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 우정원
- Founded
- Jun 2013
- Listed
- Dec 2019
- Listed shares
- 34,275,121
- Fiscal year ends
- Month 12
- Website
- www.medpacto.com
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent news
MedFactory Adds Mid-Dose Cohort to Phase 2 Trial of Vactosertib for Osteosarcoma… Approved by U.S. FDA
Predicted impact: Low
Trial cohort addition with FDA approval, early-stage and no revenue size given.
Recent filings
See all- Major management matter relevant to investorsOct 19, 2026
- Major management matter relevant to investorsOct 2, 2026
- Amended: Major management matter relevant to investorsSep 18, 2026
- Amended: Major management matter relevant to investorsSep 18, 2026
- Major management matter relevant to investorsSep 18, 2026
Titles in Korean until English translations are added.
Also known as: MedPacto / 메드팩토 / 235980 / KRX:235980
Source: KRX statistical information